tetano
Editor, Senior Moderator
J Int Med Res
. 2022 Mar;50(3):3000605221082875.
doi: 10.1177/03000605221082875.
Special case of a patient in the blast phase of chronic myeloid leukemia successfully treated with tocilizumab during critical SARS-CoV-2 infection
Amine Bouchlarhem[SUP] 1 2 [/SUP], Ounci Es-Saad[SUP] 1 2 [/SUP], Leila Haddar[SUP] 1 2 [/SUP], Oussama Lamzouri[SUP] 1 2 [/SUP], Ghizlane Elaidouni[SUP] 1 2 [/SUP], Hamza Mimouni[SUP] 1 2 [/SUP], Houssam Bkiyar[SUP] 1 2 3 [/SUP], Brahim Housni[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
The medical care of patients with hematological malignancies who develop coronavirus disease 2019 (COVID-19) has been a major challenge during the current pandemic. We herein describe a patient in the blast phase of chronic myeloid leukemia who was hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The patient was successfully treated with tocilizumab, and intubation was avoided. The severity of SARS-CoV-2 infection is mostly related to a severe acute respiratory distress syndrome that develops secondary to cytokine release syndrome, and interleukin 6 is the main cytokine involved in cytokine release syndrome. Very few reports have described the use of tocilizumab in patients with hematologic malignancies who develop SARS-CoV-2 infection, although a few cases of patients with multiple myeloma have been reported. To our knowledge, however, this is the first report of a SARS-CoV-2-infected patient in the blast phase of chronic myeloid leukemia who had a favorable response to treatment with tocilizumab. The management of patients with hematological malignancies who become infected with SARS-CoV-2 is a major challenge for practitioners, necessitating more specific research in this direction.
Keywords: Coronavirus disease 2019; blast phase; chronic myeloid leukemia; hematological malignancy; interleukin 6; tocilizumab.
. 2022 Mar;50(3):3000605221082875.
doi: 10.1177/03000605221082875.
Special case of a patient in the blast phase of chronic myeloid leukemia successfully treated with tocilizumab during critical SARS-CoV-2 infection
Amine Bouchlarhem[SUP] 1 2 [/SUP], Ounci Es-Saad[SUP] 1 2 [/SUP], Leila Haddar[SUP] 1 2 [/SUP], Oussama Lamzouri[SUP] 1 2 [/SUP], Ghizlane Elaidouni[SUP] 1 2 [/SUP], Hamza Mimouni[SUP] 1 2 [/SUP], Houssam Bkiyar[SUP] 1 2 3 [/SUP], Brahim Housni[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 35301903
- DOI: 10.1177/03000605221082875
Abstract
The medical care of patients with hematological malignancies who develop coronavirus disease 2019 (COVID-19) has been a major challenge during the current pandemic. We herein describe a patient in the blast phase of chronic myeloid leukemia who was hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The patient was successfully treated with tocilizumab, and intubation was avoided. The severity of SARS-CoV-2 infection is mostly related to a severe acute respiratory distress syndrome that develops secondary to cytokine release syndrome, and interleukin 6 is the main cytokine involved in cytokine release syndrome. Very few reports have described the use of tocilizumab in patients with hematologic malignancies who develop SARS-CoV-2 infection, although a few cases of patients with multiple myeloma have been reported. To our knowledge, however, this is the first report of a SARS-CoV-2-infected patient in the blast phase of chronic myeloid leukemia who had a favorable response to treatment with tocilizumab. The management of patients with hematological malignancies who become infected with SARS-CoV-2 is a major challenge for practitioners, necessitating more specific research in this direction.
Keywords: Coronavirus disease 2019; blast phase; chronic myeloid leukemia; hematological malignancy; interleukin 6; tocilizumab.